We found only NAFLD patients within the lean cohort showed dysregulated apolipoproteins such as APOH, APOB, APOC2, and APOC3, implying that their lipid metabolism problems may differ from those of overweight or obese populations. This evidence concerns the gene APOB and metabolic dysfunction-associated steatotic liver disease.